FLT3 and acute myeloid leukemia: Although drawing definitive conclusions from the multivariable analyses is difficult because of the generally poor treatment outcome of older patients with AML, we found that such mutations included in the 2022 ELN genetic-risk classification as FLT3-ITD, NPM1 and TP53 mutations were among main factors affecting CR rates and survival (Supplementary Table 5).